1
|
Takeda Y, Nonaka Y, Yanagie H, Yoshizaki I, Eriguchi M. Correlation between timing of surgery in relation to the menstrual cycle and prognosis of premenopausal breast cancer patients. Biomed Pharmacother 2002; 55 Suppl 1:133s-137s. [PMID: 11774860 DOI: 10.1016/s0753-3322(01)90018-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The timing of surgery in relation to menstrual phase might affect the progress of disease in premenopausal women with operable breast cancer. In the present study, the records were examined of 28 such cases treated between 1990 and 1999, and compared for recurrence-free survival with reference to the phases of the menstrual cycle defined by Hrushesky and Senie. During the follow-up period, breast cancer relapse occurred in five patients, and one patient died of another disease unconnected with recurrent breast cancer. The recurrence rate was not significantly different between two phases classified by either Hrushesky or Senie. However, patients with early-stage breast cancer operated during the perimenstrual phase and those with advanced breast cancer which was resected during the peri-ovulatory phase appeared to have a better prognosis than patients operated on during the other phases. Since the prognosis for breast cancer patients is dependent not only on the menstrual cycle but also on many other factors, it is concluded that the menstrual cycle cannot constitute an absolute prognostic factor.
Collapse
Affiliation(s)
- Y Takeda
- Department of Surgery, Institute of Medical Science, University of Tokyo, Japan.
| | | | | | | | | |
Collapse
|
2
|
Paradiso A, Serio G, Fanelli M, Mangia A, Cellamare G, Schittulli F. Predictability of monthly and yearly rhythms of breast cancer features. Breast Cancer Res Treat 2001; 67:41-9. [PMID: 11518465 DOI: 10.1023/a:1010658804640] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
In order to evaluate if breast cancer biological characteristics undergo significant menstrual and seasonal variations, we analysed in a consecutive series of 905 breast cancer patients, steroid receptor level (ER and PgR by DCC assay), proliferative activity (3H-Thymidine Labeling Index, 3H-TLI) and size of primary tumour in relation to calendar date and day of menstrual cycle at the time of the surgical procedure. For data analysis, the method of time series construction and classical spectral analyses with Bartlett Kolmogorov-Smirnov test for white noise (BKS test) was utilised. For what concerns menstrual variations, 3H-TLI showed a significant periodicity (t = 0.3146, p < 0.01 by BKS test) with peaks at day 12nd and day 18th; ER showed a significant periodicity (t = 0.3605, p < 0.01 by BKS test) with more evident peak at day 27th; PgR, a significant periodicity (t = 0.160, p = 0.05 by BKS test) with peaks at day 15th and day 24th, similar to that observed for tumour size (t = 0.19, p < 0.05 by BKS test). With respect to yearly fluctuations, 3H-TLI showed only a trend for a significant rhythm (t = 0.16, p = 0.06 by BKS test) with peaks in May and November; ER a significant periodicity (t = 0.2099, p < 0.05 by BKS test) with two evident peaks in January and April; also for PgR a significant periodicity (t = 0.3161, p < 0.05 by BKS test) was demonstrated with a peak in July; finally, tumour size showed a significant rhythm (t = 0.335, p < 0.01) paralleling 3H-TLI behaviour. Finally, the analysis of variance with interaction of menstrual and seasonal timings showed that only the seasonal timing was able to independently influence the 3H-TLI variations (3H-TLI higher in spring). We confirmed that breast biology has significant menstrual and seasonal variations and that the seasonality is probably the timing factor more relevant in periodicity determination.
Collapse
Affiliation(s)
- A Paradiso
- Clinical Experimental Oncology Laboratory, National Oncology Institute of Bari, Italy.
| | | | | | | | | | | |
Collapse
|
3
|
Affiliation(s)
- W J Hrushesky
- WJB Dorn DVA Medical Center, Columbia, South Carolina 29209, USA.
| |
Collapse
|
4
|
Kroman N, Thorpe SM, Wohlfahrt J, Andersen KW, Mouridsen HT. Variations in prognostic factors in primary breast cancer throughout the menstrual cycle. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 2000; 26:11-6. [PMID: 10718172 DOI: 10.1053/ejso.1999.0732] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
AIMS We investigated whether menstrual cycle dependent variations in prognostic factors are detectable in malignant breast tissue. METHODS Since 1977 the Danish Breast Cancer Cooperative Group has collected population-based information about primary clinical data, treatment regimens and follow-up status on Danish women with breast cancer. Information about last menstrual periods prior to surgery was obtained from files recorded at the time of admission for primary surgery. Included in this study were 1060 patients self-reported to be regularly menstruating and with a menstrual period within 6 weeks of surgery and who were operated in a single-step procedure. None of the patients were current users of exogenous hormones at the time of surgery. Variations of prognostic factors throughout the menstrual cycle were evaluated. RESULTS Overall, no significant correlation between endogenous hormone fluctuations and oestrogen receptor (ER) status and progesterone receptor (PgR) status were found. Furthermore, we observed no cycle-dependent variation for mitotic index, lymph node involvement or tumour size. CONCLUSIONS The classical prognostic factors in breast cancer did not differ significantly throughout the menstrual cycle in the present study.
Collapse
Affiliation(s)
- N Kroman
- Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen.
| | | | | | | | | |
Collapse
|
5
|
Pujol P, Daurès JP, Brouillet JP, Maudelonde T, Rochefort H, Grenier J. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer. Br J Cancer 1999; 79:909-14. [PMID: 10070889 PMCID: PMC2362656 DOI: 10.1038/sj.bjc.6690145] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Many studies have addressed the clinical value of pS2 as a marker of hormone responsiveness and of cathepsin D (Cath D) as a prognostic factor in breast cancer. Because pS2 and Cath D are both oestrogen induced in human breast cancer cell lines, we studied the influence of the menstrual cycle phase and menopausal status at the time of surgery on the levels of these proteins in breast cancer. A population of 1750 patients with breast cancer, including 339 women in menstrual cycle, was analysed. Tumoral Cath D and pS2 were measured by radioimmunoassay. Serum oestradiol (E2), progesterone (Pg), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels at the day of surgery were used to define the hormonal phase in premenopausal women. There was a trend towards a higher mean pS2 level in the follicular phase compared with the luteal phase (17 ng mg(-1) and 11 ng mg(-1) respectively, P = 0.09). Mean pS2 was lower in menopausal patients than in women with cycle (8 ng mg(-1) and 14 ng mg(-1) respectively, P = 0.0001). No differences in mean Cath D level were observed between the different phases of the menstrual cycle, or between pre- and post-menopausal women. In the overall population, pS2 was slightly positively associated with E2 and Pg levels and negatively associated with FSH and LH, probably reflecting the link between pS2 and menopausal status. In premenopausal women, no association was found between pS2 and E2, Pg, FSH or LH levels. There were no correlations between Cath D level and circulating hormone levels in the overall population. However, in the subgroup of premenopausal women with ER-positive (ER+) tumours, E2 was slightly associated with both pS2 and Cath D, consistent with oestrogen induction of these proteins in ER+ breast cancer cell lines. There are changes in pS2 level in breast cancer throughout the menstrual cycle and menopause. This suggests that the choice of the pS2 cut-off level should take the hormonal status at the time of surgery into account. In contrast, the level of Cath D is unrelated to the menstrual cycle and menopausal status.
Collapse
Affiliation(s)
- P Pujol
- Service de Biologie Cellulaire, Centre Hospitalier Universitaire de Montpellier-Nîmes, France
| | | | | | | | | | | |
Collapse
|
6
|
Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet P, Grenier J. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 1998. [DOI: 10.1002/(sici)1097-0142(19980815)83:4<698::aid-cncr10>3.0.co;2-n] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
7
|
Silvestrini R, Luisi A, Daidone MG, Di Mauro MG. Effect of menstrual phase on cell proliferative rate of breast cancer. Breast Cancer Res Treat 1998; 48:93-4. [PMID: 9541194 DOI: 10.1023/a:1005917412174] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- R Silvestrini
- Oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | |
Collapse
|
8
|
Abstract
PURPOSE AND DESIGN This is a critical review of the growing body of data, 32 retrospective studies of the outcomes of 9,665 women published since 1989, relevant to the possibility that the timing of primary breast cancer resection within the menstrual cycle impacts breast cancer recurrence and/or spread and patient survival. This article evaluates and contrasts the adequacy of information and data analysis presented in each publication. The overall purpose of this exercise is to rigorously determine the relative strength of the hypothesis that the menstrual cycle timing of operation impacts outcome and, thereby, to determine whether or not a specific change in the practice of breast surgical oncology can be recommended. RESULTS The single most completely reported and thoroughly analyzed series, involving 1,175 young women, indicates that surgical resection timing is likely to be relevant to outcome. Seven additional high-quality studies involving 2,864 women have been most completely reported. While two of these eight find no impact, six (75%) of these studies find that breast cancer outcome is affected by operative timing. Nine of the remaining 24 less-complete studies report a statistically significant effect of operative timing. Among these 15 studies of the fates of more than 5,000 women, the opportune menstrual cycle phase almost invariably includes the putative luteal phase. A large number of retrospective studies of widely varying quality find no outcome difference as a function of resection timing. The adequacy of design of each of four ongoing prospective studies is found lacking. CONCLUSIONS Although it is likely that the menstrual cycle phase of operation is relevant to outcome, the nature of the available data cannot allow a clear recommendation of precisely when to operate. It is, therefore, concluded that current retrospective data are inadequate to recommend an immediate change in practice. Prospective studies of this potentially important question are essential. The prospective trials initiated to date will not be able to definitively answer this question because of inadequate chronobiological design. The minimal requirements for adequate prospective study are delineated.
Collapse
Affiliation(s)
- A A Hagen
- Free University Berlin, Department of Obstetrics and Gynecology, University Medical Center Benjamin Franklin, Germany
| | | |
Collapse
|
9
|
HRUSHESKY WILLIAMJ. Breast Cancer, Timing of Surgery, and the Menstrual Cycle: Call for Prospective Trial. J Womens Health (Larchmt) 1996. [DOI: 10.1089/jwh.1996.5.555] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
King RJ. William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis. Breast Cancer Res Treat 1993; 27:3-15. [PMID: 8260728 DOI: 10.1007/bf00683189] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The influences of estrogen and progestin on human mammary neoplasia are reviewed with a view to identifying what is known about their effects. Estrogens promote growth of established cancer and pharmacological levels of progestins induce remission. In vivo, highest proliferation of histologically normal mammary epithelium occurs in the progestogenic phase of the menstrual cycle or under the progestogenic influence of oral contraceptives. Little additional hard data exist to indicate whether progestins promote or inhibit human mammary carcinogenesis. Effects on proliferation, steroid receptor content and development are discussed together with interpretation of epidemiological data on risk factors that have hormonal components. Progestins may not be the benign or beneficial agents previously supposed, and there are virtually no data to suggest that they are antiestrogenic. It is hypothesized that carcinogenesis may be accompanied by increased sensitivity to estrogen, which provides a growth advantage to the tumor by maximizing use of the low estrogen concentrations encountered in the postmenopausal state.
Collapse
Affiliation(s)
- R J King
- School of Biological Sciences, University of Surrey, Guildford, United Kingdom
| |
Collapse
|
11
|
Abstract
Oestrogens and progestins are important for both the genesis of human breast cancer and growth of those tumours once formed. Their role at different stages of the neoplastic process are reviewed and discussed within the context of a change in sensitivity of epithelial cells during either initiation or promotion stages. Evidence favours, but does not conclusively prove, the view that progestins are the predominant mitogen for normal breast epithelium whilst oestrogen assumes that function in neoplastic epithelium. Alterations in oestrogen receptor levels could provide the key for such a change. There are insufficient data on physiological progestin concentrations to judge their effect on established cancer. Models for steroidal effects on cell proliferation and oestrogen and progestin receptor regulation that are based on endometrial data are not appropriate for breast.
Collapse
Affiliation(s)
- R J King
- School of Biological Sciences, University of Surrey, Guildford, England
| |
Collapse
|
12
|
Ruiz-Torres A. Basic results for assessment of human ageing. Arch Gerontol Geriatr 1991; 12:261-72. [PMID: 15374453 DOI: 10.1016/0167-4943(91)90033-m] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/1990] [Accepted: 12/13/1990] [Indexed: 10/27/2022]
Abstract
The study of collagen metabolism during the total life span of mammals has contributed greatly to the understanding of the human ageing process. Particularly relevant is the demonstration that these tissue dynamics of collagen in the whole organism is clearly age-dependent, but progresses non-synchronously in different organs. Thus, supply and degradation are tightly linked processes in all tissues, as in the case of other proteins, but the catabolic process regulates the turnover of already deposited collagen in adaptation to local needs. In the whole body there is a similar age-dependent interaction regarding the part of the organism whose activity is directly related with regulating functions mainly supporting the parenchyma, the other part of the organism to work as well as possible. It can be deduced that this regulation attains great importance in ageing because the capacity to survive is dependent on it. At the same time as we expose this dynamical conception of ageing we point out some ageing parameters from experimental gerontology capable of being applied in such a manner as to objectify human ageing manifestations. Furthermore, we propose a way to quantify total ageing on the basis of this interaction, as in a two-compartment system leading to one result which would mean vitality. We discuss related questions, mainly regarding the reference population as control and a good parameter selection which should represent total ageing manifestations in the human body.
Collapse
Affiliation(s)
- A Ruiz-Torres
- Instituto Universitario de Investigación Gerontológica y Metabólica, Universidad Autónoma de Madrid, Madrid, Spain
| |
Collapse
|
13
|
Smyth CM, Benn DE, Reeve TS. Influence of the menstrual cycle on the concentrations of estrogen and progesterone receptors in primary breast cancer biopsies. Breast Cancer Res Treat 1988; 11:45-50. [PMID: 3382762 DOI: 10.1007/bf01807557] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
There is controversy in the literature regarding the effects of endogenous hormones on estrogen receptors (ER) and progesterone receptors (PR) in young women with breast cancer. We studied 117 young women with primary breast cancer and assessed their breast biopsies for ER and PR. The women had a record of their last menstrual period prior to breast biopsy. The menstrual cycle was divided into four phases--early proliferative (days 1-7), late proliferative (days 8-15), early secretory (days 16-22), and late secretory (days 23-30). There were lower levels of both ER and PR in biopsies excised during the early secretory phase than in other phases of the cycle; early proliferative phase receptor positive medians of ER = 77 fmol/mg protein and PR = 467 fmol/mg protein fell to ER = 28 fmol/mg and PR = 128 fmol/mg protein in the early secretory phase.
Collapse
Affiliation(s)
- C M Smyth
- Department of Surgery, University of Sydney, Royal North Shore Hospital, St. Leonards N.S.W., Australia
| | | | | |
Collapse
|
14
|
Axelrod DM, Menendez-Botet CJ, Kinne DW, Osborne MP. Levels of estrogen and progesterone receptor proteins in patients with breast cancer during various phases of the menses. Cancer Invest 1988; 6:7-14. [PMID: 3365573 DOI: 10.3109/07357908809077024] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Analysis of estrogen and progesterone receptor proteins was carried out in 75 premenopausal and 79 postmenopausal patients with primary operable breast carcinoma who were treated from January 1983 to December 1984. The frequency of estrogen receptor protein positive/progesterone receptor protein positive (+/+); estrogen receptor protein negative/progesterone receptor protein negative (-/-); estrogen receptor protein negative/progesterone receptor protein positive (-/+); and estrogen receptor protein positive/progesterone receptor protein negative (+/-) was 40.5%, 30.5%, 23%, and 6% in premenopausal patients, respectively, and 52%, 24%, 2.5%, and 21.5% in postmenopausal patients, respectively (p less than 0.001). The mean positive estrogen receptor protein concentration (expressed as femtomoles per milligram of protein +/- SEM) was significantly higher in postmenopausal patients (54 +/- 6) than in premenopausal patients (19 +/- 2) (p less than 0.005). The progesterone receptor protein values did not differ significantly between these two groups. The phase of the menstrual cycle was recorded at the time of surgery in the 75 premenopausal women. Maximum receptor positivity occurred in the secretory phase, however, this difference is not statistically significant, and our data suggest that there are no distributional differences between the phase of menses and positivity of estrogen and progesterone receptor proteins. Future studies which included analyses of circulating sex steroid levels and receptor proteins will provide a better understanding of complex hormonal regulatory mechanisms which exist in patients with breast cancer.
Collapse
Affiliation(s)
- D M Axelrod
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
| | | | | | | |
Collapse
|
15
|
Weimer DA, Donegan WL. Changes in estrogen and progesterone receptor content of primary breast carcinoma during the menstrual cycle. Breast Cancer Res Treat 1987; 10:273-8. [PMID: 3447646 DOI: 10.1007/bf01805764] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
This study was undertaken to determine if hormone receptor activity in breast cancers changes during different phases of the menstrual cycle. Estrogen (ER) and progesterone (PgR) receptors in seventy-eight primary breast carcinomas from premenopausal women were compared with the phase of the menstrual cycle at the time of biopsy. The frequency of ER positivity did not change, but PgR positivity became significantly higher after the early follicular phase. An increase in mean ER and PgR concentration was found (p less than .05) in the late luteal phase. The results indicate that tumor ER and PgR values change during the menstrual cycle, probably in response to endogenous hormonal fluctuations, and this may account for some vicissitudes in establishing hormone dependence.
Collapse
Affiliation(s)
- D A Weimer
- Department of Surgery, Medical College of Wisconsin, Milwaukee
| | | |
Collapse
|
16
|
Lopes MT, Liberato MH, Widman A, Brentani MM. Occupied and unoccupied type II estrogen binding sites in human breast cancer. JOURNAL OF STEROID BIOCHEMISTRY 1987; 26:219-26. [PMID: 3560938 DOI: 10.1016/0022-4731(87)90075-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Using a saturation analysis over a wide range of [3H]estradiol at two temperatures 4 and 22 degrees C we have determined unoccupied (4 degrees C) and total (22 degrees C) type II estrogen binding site (EBS) levels in individual cytosols of 100 patients with breast cancer (50 post and 50 premenopausal). Exchange was found to be complete after 18 h at 22 degrees C and receptor degradation was negligible during this treatment. Steroid specificity and affinity determined by Scatchard and Rosenthal plot analysis were not altered at 22 degrees C. Carcinomas presented a higher total type II REBS level as compared unfilled type II binding sites or the classical ER, independently of menopausal status, phase of the menstrual cycle or positivity of ER. On the other hand, unoccupied type II EBS level was strongly correlated to the concentration of type I ER, being higher on the post-menopausal group and older patients.
Collapse
|